Status of a Unique Vaccine against hCG for Contraception and Advanced Stage Cancers expressing ectopically hCG

Talwar GP, Singh P, Gupta JC

Mitteilungen aus der Redaktion

Besuchen Sie unsere Rubrik

✓ Medizintechnik-Produkte

Neues CRT-D Implantat
Intica 7 HFT QP von Biotronik

Artis pheno
Siemens Healthcare Diagnostics GmbH

Philips Azurion:
Innovative Bildgebungslösung

Aspirator 3
Labotect GmbH

InControl 1050
Labotect GmbH

e-Journal-Abo

Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.
Die Lieferung umfasst 4–5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.
Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

✓ Bestellung e-Journal-Abo

Haftungsausschluss


Bitte beachten Sie auch diese Seiten:
Impressum
Disclaimers & Copyright
Datenschutzerklärung
**Linkage to a useful Carrier**

HCG is composed of 2 subunits, alpha and beta (Fig. 1). The alpha subunit is common to 3 other pituitary hormones: TSH, LH, FSH, hence β subunit of HCG was chosen to make the vaccine. HCGβ was linked to tetanus toxoid (TT), an immuno-prophylactic vaccine available in plenty at low cost, not only because it can mobilize T cell help to render B cells competent to make humoral response, but also because it can protect women from dying, following deliveries taking place in aseptic conditions. In the 1970’s antenatal tetanus was a major killer of women in India.

hCGβ linked to TT indeed induced anti-hCG and anti-tetanus antibodies in all 4 women who opted for this investigation. They had completed their families and had undergone tubectomy [2, 3]. Figure 2 is representative of their immune response.

In order to test whether the circulating antibodies generated by the β subunit of hCG recognized the dimer, the biologically active hCG was given intravenously which led to decline in titer of anti-hCG antibodies indicating their binding with the administered hCG (Fig. 3). The titres of antibodies returned to previous levels in course of time, which was again a desirable feature.

Thus by the carrier linkage approach, it was possible to render hCG immuno-
genic in women. However the titres of antibodies generated by hCG-β-TT vaccine were fairly low. Thus the immunogenicity of the vaccine had to be improved.

**Hetero-Species Dimer**

We conceptualized the linkage of β subunit of hCG with alpha subunit of ovine LH [4]. The ability of α and β subunits to associate with each other is conserved across species in mammals. In this way, not only will a dimer be presented to the immune system to react against, but also a foreign alpha protein will be more strongly reacted against by the immune system. Indeed the Hetero-species dimer (HSD) linked to TT, or Diphtheria toxoid (DT) or Cholera toxin B subunit (CHB) generated higher titres [4] than hCG-β-TT (Tab. 1).

**Safety and Efficacy of the HSD-TT/DT Vaccine**

The next obvious question was whether this vaccine was safe for human usage, reversible and competent to prevent pregnancy in sexually active women.

After due Regulatory and Ethics committees approval, phase 1 followed by phase 2 clinical trials were conducted on the HSD-TT/DT vaccine in major institutions of India, such as the All India Institute of Medical Sciences, New Delhi & Postgraduate Institute of Medical Education & Research, Chandigarh.

The vaccine was devoid of toxicity and was reversible [5, 6]. The most important finding was that circulating antibodies against hCG indeed prevent women of proven fertility, who were sexually active women.

**Table 1.** Immunogenecity & Bioneutralization capacity of Antibodies generated by HSD-TT/CHB (Hetero-species dimer linked to B subunit of Cholera toxin) as compared to hCGβ-CHB in rats (n = 6). Mod. from [3]. © G. P. Talwar

<table>
<thead>
<tr>
<th>Immunogen</th>
<th>hCG binding capacity (pg) (Range)</th>
<th>hCG bio-neutralization potency (pg) (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>hCGβ-CHB</td>
<td>27.1 ± 1.7 (25–33)</td>
<td>17.1 ± 1.2 (13–21)</td>
</tr>
<tr>
<td>HSD-CHB</td>
<td>32.5 ± 1.4 (29–36)</td>
<td>26.1 ± 0.8 (23.5–28.0)</td>
</tr>
</tbody>
</table>

**Table 2.** Pregnancy in 4 women who conceived at low anti-hCG titres. All of them delivered normal children. © G. P. Talwar

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age (Yrs)</th>
<th>Parity</th>
<th>Antibody titres ng/ml hCG bioneutralization</th>
<th>Antenatal history</th>
<th>Delivery</th>
<th>Gestation (weeks)</th>
<th>Birth weight (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NMT</td>
<td>28</td>
<td>3</td>
<td>20</td>
<td>No problem</td>
<td>Elective LSCS</td>
<td>38</td>
<td>2800</td>
</tr>
<tr>
<td>URM</td>
<td>28</td>
<td>2</td>
<td>5</td>
<td>One episode of swelling of parotids at 6 weeks gestation</td>
<td>SVD</td>
<td>35</td>
<td>2570</td>
</tr>
<tr>
<td>GTD</td>
<td>24</td>
<td>3 (2 live)</td>
<td>5</td>
<td>Recurrent vomiting and loose motions, PIH</td>
<td>SVD</td>
<td>36</td>
<td>1840</td>
</tr>
<tr>
<td>ANT</td>
<td>35</td>
<td>2</td>
<td>10</td>
<td>No problem</td>
<td>Elective LSCS</td>
<td>38</td>
<td>2700</td>
</tr>
</tbody>
</table>

LSCS: Lower segment Cesarian section; SVD: Spontaneous vaginal delivery
Unique Vaccine against hCG for Contraception and Advanced Stage Cancers

tive, from becoming pregnant. Only one pregnancy took place in 1224 cycles in women having a titer of 50 ng/ml or more of anti-hCG antibodies. Eight women completed > 30 cycles without becoming pregnant, 9 between 24 and 29 cycles, 12 completed 18–23 cycles, 15, 12–17 cycles and 21 subjects had completed 6–11 cycles of continuous exposure to the risk of pregnancy without becoming pregnant. Women kept on ovulating normally and had regular menstrual cycles. Immunization had no adverse effect on ovulation. Luteal phase progesterone continued to indicate normal ovulation of the immunized women. Menstrual cycles were undisturbed and continued to be as regular as before immunization (Fig. 4). No change was noticeable in bleeding profiles. These findings confirmed the achievements expected from choosing a target, which is not normally involved in reproductive functions of a non-pregnant healthy female.

Reversibility and Normalcy of Progeny born to previously Immunized Women

In case boosters were not given, the antibodies declined over time. They readily conceived when titres went below 30 ng/ml of titres (Fig. 5).

A pertinent issue was whether women becoming pregnant at low titres would have normal pregnancy and whether the progeny born would not be adversely affected by prior immunization against hCG. A senior pediatrician surveyed carefully the record of 4 women, who had decided to have another child, after a gap of protection from pregnancy by the vaccine (Tab. 2). Two women delivered term babies by elective caesarian section and other two delivered full-term babies by spontaneous vaginal delivery. None of the babies suffered from birth asphyx-

Reversibility and Normalcy of Progeny born to previously Immunized Women

In case boosters were not given, the antibodies declined over time. They readily conceived when titres went below 30 ng/ml of titres (Fig. 5).

A pertinent issue was whether women becoming pregnant at low titres would have normal pregnancy and whether the progeny born would not be adversely affected by prior immunization against hCG. A senior pediatrician surveyed carefully the record of 4 women, who had decided to have another child, after a gap of protection from pregnancy by the vaccine (Tab. 2). Two women delivered term babies by elective caesarian section and other two delivered full-term babies by spontaneous vaginal delivery. None of the babies suffered from birth asphyx-
Unique Vaccine against hCG for Contraception and Advanced Stage Cancers

There was no evidence of any congenital malformation in any of the babies. In conclusion, the anti-fertility effect of hCG vaccine is not only reversible at low titres of antibodies, but when desired the pregnancy progresses uneventfully to successful completion without any hazard to the mother [7].

Revival and Development of a Recombinant Vaccine

After a gap of 12 years, GPT was asked by an Indo-US Committee on Contraception Research to revive the vaccine. Meanwhile genetic engineering techniques had emerged. We decided to make a recombinant vaccine, which if successful, would be amendable to industrial production. We linked hCG-β gene at C-terminal to B subunit of heat labile enterotoxoid of E. coli (Fig. 6). This carrier would have the additional advantage of imparting mucosal immunity. hCG-β-LTB is immunogenic and induces along with heat-killed Mycobacterium indicus pranii (MiP) as adjuvant, very high antibody titres in BALB/c mice (Fig. 7) [8]. It is also immunogenic in mice of 4 other genetic strains [9]. MiP is an atypical non-pathogenic mycobacteria developed by us as an immunotherapeutic vaccine against leprosy [10]. It is approved by the Drugs Controller General of India (DCGI) and by the US FDA. It is a potent invigorator of immune responses. It is being used as adjunct to multidrug regimen for treatment of category II (difficult to treat) tuberculosis patients. What is amazing is that it has both preventative & therapeutic action against SP20 Myeloma in mice (Fig. 8) as observed by Dipankar Nandi et al [11] at the Indian Institute of Science, Bangalore. This Mycobacteria has now been sequenced and being hitherto not listed in World Data Book, it has been named Mycobacterium indicus pranii [12]. Pran is my first name; NII is the National Institute of Immunology, where developmental work and trials on this mycobacterium were carried out.

Going back to Clinical trial on the Recombinant hCGβ-LTB Vaccine

Being a genetically engineered vaccine it was put up to the National Review Committee on Genetic Manipulation (RCGM). RCGM has approved the hCGβ-LTB recombinant vaccine after cross-checking the consistency of the product made in 3 Batches of production. The Committee also approved the fairly exhaustive Protocol for conduct of Toxicology in 2 species of rodents by a GLP company of international standard. Toxicology has been done. It is fully safe.
Unique Vaccine against hCG for Contraception and Advanced Stage Cancers

by all criteria and is also free of mutagenicity and causing skin sensitization. We were also able to conduct safety and immunogenicity studies on the recombinant hCG-β-LTB vaccine in a subhuman primate species, the marmosets at the National Institute of Research in Reproduction (NIRRH), Mumbai. These have also been completed and the vaccine found fully safe. Marmosets offered an additional opportunity to test whether the antibodies prevented pregnancy in marmosets. 8/9 immunized marmosets were protected from becoming pregnant on co-habitation with fertile males, whereas all non-immunized marmosets in the control group became pregnant.

Technology for producing the vaccine under GMP conditions has been transferred to a recognized biotech company. The vaccine prepared by the company has been cross-checked for physicochemical traits and immunogenicity.

The Indian Council of Medical Research has constituted an Expert Committee to develop a protocol for safety & immunogenicity, the phase I trial of the hCGβ-LTB vaccine in women of proven fertility. The Committee has already met and finalized the protocol. It will now go to the Ethics Committees & Drugs Controller General of India for approval for starting the trial.

Potential utility of the Anti-hCG vaccine & Anti-hCG antibodies in Advanced stage Terminal Cancers

A number of reports have appeared in the literature on the expression of hCG or its subunits by a variety of cancers particularly at the advanced stage. Expression of alpha subunit of hCG was observed in lung carcinoma [13]. One third of transitional cell carcinomas of bladder ectopically produce trophoblastic hormones that are specifically correlated with stage and grade of the tumor [14]. hCG-β was made ectopically and reported as a poor prognostic marker in colorectal cancer [15]. More than 40% of pancreatic exocrine tumors produce hCG-β [16]. Determination of hCG-β in serum was considered as a potential marker in the prognostic evaluation of patients with squamous cell carcinoma of the oral cavity and oropharynx [17]. The survival of women suffering from cervical carcinoma in whom the tumor secreted hCG-β was poorer (14%) as compared to those negative for hCG-β (75%) [18]. Invariably at the stage that ectopic expression of hCG/subunits takes place, the cancer is advanced and refractory to the currently available drugs. Can active ± passive immunization of the patients against hCG be helpful in prolonging their life?

A few studies done in our laboratory on cancer cells derived from patients dying of such cancers are encouraging. Anti-hCG antibodies were inhibitory to the growth of A549 cells in vitro in a dose-dependent manner (Fig. 9).
Many years back we reported the anti-cancerous effect of anti-hCG-β antibodies on growth of Chago lung cancer expressing this subunit in nude mice [19]. The anti-cancerous effect of inactivation of hCG by bioeffective antibodies is understandable on the grounds that hCG promotes the multiplication of cells, overcoming apoptosis [20]. It promotes also angiogenesis and invasiveness [21].

Targeted delivery of Curcumin, a safe Anti-Cancerous Compound

Curcumin (Diferuloylmethane) has anti-inflammatory and anti-cancerous properties. It is highly safe, doses upto 8 mg per day show no ill effect of any sort. It is hydrophobic, but can be rendered hydrophilic by linking it to an antibody. PiPP, a monoclonal antibody against hCG linked to curcumin, kills 100% of MOLT-4 lymphoblastic leukemia cells in culture [22]. Figure 10 shows the cytosis of MOLT-4 cells with PiPP-curcumin conjugate.

Summary & State of Art

Human chorionic gonadotropin (hCG) has proven to be a right target for immunological intervention. Pregnancy is prevented in sexually active women at and above 50 ng/ml of antibody titres with out impairment of ovulation, regularity of menstrual cycles and normal bleeding profiles. Fertility is regained without delay on decline of antibodies below 30 ng/ml. Though observations are based on few numbers, progeny born to previously immunized women are normal in their developmental landmarks and cognitive abilities.

A recombinant vaccine (hCGβ-LTB) has been developed, which assures consistency of the linkage of the ‘carrier’ to the β subunit of hCG in the product. The vaccine is highly immunogenic in mice. The vaccine has received the approval of the Regulatory Committee on Genetically Made Products. The technology has been transferred to a biotech company which will make available the vaccine prepared under GMP conditions. The recombinant vaccine has completed safety and toxicology studies in 2 species of rodents and in a subhuman primate Marmosets. It is poised to go back to clinical trials under the aegis of the Indian Council of Medical Research.

The vaccine is likely to find additional therapeutic use in advanced stage cancers expressing ectopically hCG, alone or along with monoclonal antibodies against hCG and those linked to curcumin.

Acknowledgements

Revival of the work on the hCG vaccine has benefited from research support of the Indo-US co-operation in contraception. Research grants from the Department of Biotechnology, Government of India and the Indian Council of Medical Research are gratefully acknowledged.

Conflict of Interest

The authors declare no conflict of interest.

References:

Mitteilungen aus der Redaktion

Die meistgelesenen Artikel

Speculum

Journal für Reproduktionsmedizin und Endokrinologie